Imaging of tumor angiogenesis: Current approaches and future prospects

Current Pharmaceutical Design

Volumn 12, Issue 21, 2006, Pages 2661-2672

  Daldrup, Heike E ^a   Simon, Gerhard H ^a   Brasch, Robert C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis imaging; Blood pool agents; Macromolecular contrast agents

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; AXITINIB; CYCLODEXTRIN DERIVATIVE; DOXORUBICIN; GADOLINIUM CHELATE; IODINE; MONOCLONAL ANTIBODY LM 609; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; STEROID; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ENZYME ACTIVITY; FOLLOW UP; HUMAN; HYPOXIA; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; METASTASIS; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

DIAGNOSTIC IMAGING; FORECASTING; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33745755300     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777698774     Document Type: Review

References (87)

1. Yang M, Li L, Jiang P, Moossa AR, Penman S, Hoffman RM. Dual-color fluorescence imaging distinguishes tumor cells from induced host angiogenic vessels and stromal cells. Proc Natl Acad Sci USA 2003; 100: 14259-62. Epub 2003 Nov 12.
2. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-Specific Tumor Imaging with 18F-Fluoroazomycin Arabinoside. J Nucl Med 2005; 46: 106-13.
3. Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, Welch MJ. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem 2003; 14: 756-63.
4. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005; 2(97): 172-87.
5. He Q, Xu RZ, Shkarin P, Pizzorno G, Lee-French CH, Rothman DL, et al. Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer diagnosis, metabolic phenotyping, and characterization of tumor microenvironment. Dis Markers 2003; 19: 69-94.
6. Laking GR, Price PM. Positron emission tomographic imaging of angiogenesis and vascular function. Br J Radiol 2003; 76: S50-9.
7. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 2001; Suppl: 96S-103S.
8. Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2004; 45: 519-25.
9. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987; 47: 3039-51.
10. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35-52.
11. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987; 6: 559-93.
12. Cosgrove D. Angiogenesis imaging-ultrasound. Br J Radiol 2003; 76(Spec No 1): S43-9.
13. McDonald D, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003; 9: 713-719.
14. Sedelaara JPM, van Leendersb GJLH, Hulsbergen-van de Kaab CA, van der Poela HG, van der Laakb JAWM, Debruynea FMJ, et al. Microvessel Density: Correlation between Contrast Ultrasonography and Histology of Prostate Cancer Eur Urol 2001; 40: 285-293
15. Miles KA. Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 2003; 76: S36-42.
16. Lee TY, Purdie TG, Stewart E. CT imaging of angiogenesis. Q J Nucl Med 2003; 47: 171-87.
17. Fournier LS, Cuenod CA, de Bazelaire C, Siauve N, Rosty C, Tran PL, et al. Early modifications of hepatic perfusion measured by functional CT in a rat model of hepatocellular carcinoma using a blood pool contrast agent. Eur Radiol 2004; 14: 2125-33. Epub 2004 Jul 29.
18. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. Dynamic CT measurement of cerebral blood flow: a validation study. AJNR Am J Neuroradiol 1999; 20: 63-73.
19. Gillard JH, Minhas PS, Hayball MP, Bearcroft PW, Antoun NM, Freer CE, et al. Assessment of quantitative computed tomographic cerebral perfusion imaging with 142(15)O positron emission tomography. Neurol Res 2000; 22: 457-64.
20. Miles KA, Griffiths MR, Fuentes MA. Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG PET in lung nodules. Radiology 2001; 220: 548-53.
21. Padhani AR, Dzik-Jurasz A. Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging 2004; 15: 41-57.
22. Helbich TH, Roberts TP, Gossmann A, Wendland MF, Shames DM, Adachi M, et al. Quantitative gadopentetate-enhanced MRI of breast tumors: testing of different analytic methods. Magn Reson Med 2000; 44: 915-24.
23. Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000; 21: 891-9.
24. Cha S. Perfusion MR imaging: basic principles and clinical applications. Magn Reson Imaging Clin N Am 2003; 11: 403-13.
25. Gossmann A, Helbich TH, Mesiano S, Shames DM, Wendland MF, Roberts TP, et al. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am J Obstet Gynecol 2000; 183: 956-63.
26. Gossmann A, Helbich TH, Kuriyama N, Ostrowitzki S, Roberts TP, Shames DM, et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 2002; 15: 233-40.
27. Turetschek K, Floyd E, Helbich T, Roberts TP, Shames DM, Wendland WF, et al. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology. J Magn Reson Imaging 2001; 14: 237-42.
28. Turetschek K, Roberts TP, Floyd E, Preda A, Novikov V, Shames DM, et al. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. J Magn Reson Imaging 2001; 13: 882-8.
29. Turetschek K, Floyd E, Shames DM, Roberts TP, Preda A, Novikov V, et al. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology. Magn Reson Med 2001; 45: 880-6.
30. Turetschek K, Huber S, Floyd E, Helbich T, Roberts TP, Shames DM, et al. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology 2001; 218: 562-9.
31. Turetschek K, Preda A, Floyd E, Shames DM, Novikov V, Roberts TP, et al. MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model. Acad Radiol 2002; 9(Suppl 2): S519-20.
32. Turetschek K, Huber S, Helbich T, Floyd E, Tarlo KS, Roberts TP, et al. Dynamic MRI enhanced with albumin-(Gd-DTPA)30 or ultrasmall superparamagnetic iron oxide particles (NC100150 injection) for the measurement of microvessel permeability in experimental breast tumors. Acad Radiol 2002; 9(Suppl 1): S112-4.
33. Turetschek K, Preda A, Floyd E, Shames DM, Novikov V, Roberts TP, et al. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model. Eur J Nucl Med Mol Imaging 2003; 30: 448-55.
34. Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P, et al. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 2004; 20: 138-44.
35. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, et al. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. Pediatr Radiol 1998; 28: 67-78.
36. Daldrup-Link HE, Shames DM, Wendland M, Muhler A, Gossmann A, Rosenau W, et al. Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging. Acad Radiol 2000; 7: 934-44.
37. Daldrup-Link HE, Rydland J, Helbich TH, Bjornerud A, Turetschek K, Kvistad KA, et al. Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. Radiology 2003; 229: 885-92.
38. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, Rosenau W, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998; 171: 941-9.
39. Daldrup HE, Shames DM, Husseini W, Wendland MF, Okuhata Y, Brasch RC. Quantification of the extraction fraction for gadopentetate across breast cancer capillaries. Magn Reson Med 1998; 40: 537-43.
40. Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, Ferrara N, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998; 16: 225-30.
41. Roberts TP. Physiologic measurements by contrast-enhanced MR imaging: expectations and limitations. J Magn Reson Imaging 1997; 7: 82-90.
42. Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S, Masuda K, et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996; 200: 639-49.
43. Tuncbilek N, Karakas HM, Altaner S. Dynamic MRI in indirect estimation of microvessel density, histologic grade, and prognosis in colorectal adenocarcinomas. Abdom Imaging 2004; 29: 166-72.
44. van Dijke CF, Brasch RC, Roberts TP, Weidner N, Mathur A, Shames DM, et al. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology 1996; 198: 813-8.
45. Foo SS, Abbott DF, Lawrentschuk N, Scott AM. Functional imaging of intratumoral hypoxia. Mol Imaging Biol 2004; 6: 291-305.
46. Tochon-Danguy HJ, Sachinidis JI, Chan F, Chan JG, Hall C, Cher L, et al. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol 2002; 29191-7.
47. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992; 33: 2133-7.
48. 48. Groshar D, McEwan AJ, Parliament MB, Urtasun RC, Golberg LE, Hoskinson M, et al. Imaging tumor hypoxia and tumor perfusion. J Nucl Med 1993; 34: 885-8.
49. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-6.
50. Mizukami S, Kikuchi K, Higuchi T, Urano Y, Mashima T, Tsuruo T, et al. Imaging of caspase-3 activation in HeLa cells stimulated with etoposide using a novel fluorescent probe. FEBS Lett 1999; 453: 356-60.
51. Murakami Y, Takamatsu H, Taki J, Tatsumi M, Noda A, Ichise R, et al. 18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging 2004; 31: 469-74.
52. Schellenberger EA, Bogdanov A Jr, Hogemann D, Tait J, Weissleder R, Josephson L. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Mol Imaging 2002; 1: 102-7.
53. Lahorte CM, Vanderheyden JL, Steinmetz N, Van de Wiele C, Dierckx RA, Slegers G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 2004; 31: 887-919.
54. Blankenberg FG, Mandl S, Cao YA, O'Connell-Rodwell C, Contag C, Mari C, et al. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J Nucl Med 2004; 45: 1373-80.
55. Wu JC, Chen IY, Wang Y, Tseng JR, Chhabra A, Salek M, et al. Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardium. Circulation 2004; 110: 685-91.
56. Leong-Poi H, Christiansen J, Klibanov AL, Kaul S, Lindner JR. Noninvasive assessment of angiogenesis by ultrasound and micro-bubbles targeted to alpha(v)-integrins. Circulation 2003; 107: 455-60.
57. Li K CP, Bednarski MD: Vascular-targeted molecular imaging using functionalized polymerized vesicles, J Magn Reson Imaging 2002; 16: 388-393
58. McQuade P, Knight LC: Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3), Q J Nucl Med 2003; 47: 209-220
59. Marugan JJ, Haslow KD, Crysler C.: Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands. Bioorg Med Chem Lett 2004; 14: 4553-5.
60. Bremer C, Bredow S, Mahmood V, Weissleder R, Tung CH. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 2001; 221: 523-9.
61. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001; 7: 743-8.
62. Bremer C, Tung CH, Weissleder R. Molecular imaging of MMP expression and therapeutic MMP inhibition. Acad Radiol 2002; 9(Suppl 2): S314-5.
63. Pham W, Choi Y, Weissleder R, Tung CH. Developing a peptide-based near-infrared molecular probe for protease sensing. Bioconjug Chem 2004; 15: 1403-7.
64. van Dorsten FA, van der Graaf M, Engelbrecht MR, van Leenders GJ, Verhofstad A, Rijpkema M, et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004; 20: 279-87.
65. Miles KA. Functional CT imaging in oncology. Eur Radiol 2003; 13(Suppl 5): M134-8.
66. Somer EJ, Marsden PK, Benatar NA, Goodey J, O'Doherty MJ, Smith MA. PET-MR image fusion in soft tissue sarcoma: accuracy, reliability and practicality of interactive point-based and automated mutual information techniques. Eur J Nucl Med Mol Imaging 2003; 30: 54-62.
67. Steinmetz H, Huang Y, Seitz RJ, Knorr U, Schlaug G, Herzog H, et al. Individual integration of positron emission tomography and high-resolution magnetic resonance imaging. J Cereb Blood Flow Metab 1992; 12: 919-26.
68. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003; 44: 224-39.
69. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-65.
70. Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordirk F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22: 900-8.
71. Aksoy FG, Lev MH. Dynamic contrast-enhanced brain perfusion imaging: technique and clinical applications. Semin Ultrasound CT MR 2000; 21: 462-77.
72. Cohen FM, Kuwatsuru R, Shames DM, Neuder M, Mann JS, Vexler V, et al. Contrast-enhanced magnetic resonance imaging estimation of altered capillary permeability in experimental mammary carcinomas after X-irradiation. Invest Radiol 1994; 29: 970-7.
73. Aicher KP, Dupon JW, White DL, Aukerman SL, Moseley ME, Juster R, et al. Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha. Cancer Res 1990; 50: 7376-81.
74. Preda A, Novikov V, Moglich M, Turetsche K, Shames DM, Brasch RC, et al. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 2004; 20: 865-73.
75. Chaudhuri TR, Cao Z, Rodriguez-Burford C, LoBuglio AF, Zinn KR. A non-invasive approach for monitoring breast tumor cells during therapeutic intervention. Cancer Biother Radiogharm 2002; 17:205-12.
76. Eccles SA. Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention. Int J Dev Biol 2004; 48: 583-98.
77. Kurdziel KA, Figg WD, Carrasquillo JA, Huebsch S, Whatley M, Sellers D, et al. Using positron emission tomography 2-deoxy-2-[18F] fluoro-D-glucose, 11CO, and 150-water for monitoring androgen independent prostate cancer. Mol Imaging Biol 2003; 5: 86-93.
78. Daldrup-Link HE, Okuhata Y, Wolfe A, Srivastav S, S OI, Ferrara N, et al. Decrease in Tumor Apparent Permeability-Surface Area Product to a MRI Macromolecular Contrast Medium Following Angiogenesis Inhibition with Correlations to Cytotoxic Drug Accumulation. Microcirculation 2004; 11: 387-396.
79. Lee K, Erturk E, Mayer R, Cockett AT. Efficacy of antitumor chemotherapy in C3H mice enhanced by the antiangiogenesis steroid, cortisone acetate. Cancer Res 1987; 47: 5021-4.
80. Teicher BA, Sotomayor-EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992; 52(23): 6702-4.
81. Gali-Muhtasib H, Sidani M, Geara F, Mona AD, Al-Hmaira J, Haddadin MJ, et al. Quinoxaline 1,4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation. Int J Oncol 2004; 24: 1121-31.
82. Pradel C, Siauve N, Bruneteau G, Clement O, de Bazelaire C, Frouin F, et al. Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magn Reson Imaging 2003; 21: 845-51.
83. Lara PN, Jr., Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, et al. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 2003; 9: 4772-81.
84. Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J 2001; 7(Suppl 3): S120-8.
85. Ebbinghaus C, Scheuermann J, Neri D, Elia G. Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a market of tumor angiogenesis. Curr Pharm Des 2004; 10(13): 1537-49.
86. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004; 10(13): 1439-55.
87. Pomper MG, Lee JS. Small animal imaging in drug development. Curr Pharm Des 2005; 11(25): 3247-72.